October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12…
ZHENGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- In a report published by Xinhua News Agency, the finals of the China International…
Platform Democratizes Access to Real-World Asset (RWA) Investments, Merging Tangible Security with Blockchain Efficiency ROAD TOWN, British Virgin Islands, Oct.…
PANAMA CITY, Oct. 20, 2025 /PRNewswire/ -- Rocked by the sudden "black swan event" on October 11, the crypto market experienced…
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed…
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face inflation, falling interest rates, and economic uncertainty, investors…
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face inflation, currency depreciation, and rising uncertainty, investors are…
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As inflation pressures mount and global investors seek stable value amid currency…